Results 241 to 250 of about 64,289 (299)

INTRAPERITONEAL CHEMOTHERAPY

Obstetrics and Gynecology Clinics of North America, 1994
Despite high initial tumor response rates to systemically administered platinum-based chemotherapy, fewer than one quarter of advanced-stage ovarian cancer patients currently experience prolonged disease-free survival. Because persistent and relapsed disease tends to remain confined to the peritoneal cavity, the strategy of enhancing drug delivery to ...
Michael F. Flessner, Robert L. Dedrick
  +6 more sources

Intraperitoneal Chemotherapy [PDF]

International Journal of Gynecological Cancer, 2010
Objectives:Critical evaluation of the benefits of intraperitoneal (IP) chemotherapy.Methods:Critical review of the literature in support of the administration of chemotherapy via the IP route.Results:The 3 largest randomized phase III trials conducted by
Walter H. Gotlieb
openaire   +2 more sources

Pharmacology of Intraperitoneal Chemotherapy

Cancer Investigation, 1983
In this review of the pharmacology and clinical application of intraperitoneal drug administration, we have tried to acquaint the reader with the current state of the art. At this juncture it is important to outline briefly some of the major remaining questions.
C E, Myers, J M, Collins
openaire   +2 more sources

Intraperitoneal Chemotherapy with Melphalan

Annals of Internal Medicine, 1984
We administered melphalan by the intraperitoneal route to investigate its toxicity and pharmacokinetics. The drug was instilled with 2 litres of fluid and allowed to dwell in the peritoneal cavity for 4 hours. No local toxicity was detected by clinical examination, laboratory tests, or histologic examination.
S B, Howell, C E, Pfeifle, R A, Olshen
openaire   +2 more sources

Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial [PDF]

European Journal of Cancer, 2016
First-line treatment of isolated resectable colorectal peritoneal metastases remains unclear. This study (the Swedish peritoneal study) compares cytoreductive surgery and intraperitoneal chemotherapy (surgery arm) with systemic chemotherapy (chemotherapy
Bengt Glimelius
exaly   +2 more sources

Intraperitoneal Chemotherapy and Immunotherapy

1988
1. The predictive model is validated empirically; a kinetic advantage for i.p. administration of certain antineoplastic drugs exist. 2. The concentrations achieved in the peritoneum are orders of magnitude greater than those found in the plasma, so rate-limiting systemic toxicities may be avoided. 3.
B E, Wolf, P H, Sugarbaker
openaire   +2 more sources

Concepts in intraperitoneal chemotherapy

Seminars in Oncology Nursing, 1987
NTRAPERITONEAL (IP) chemotherapy is the administration of chemotherapeutic agents via a catheter into the peritoneal cavity. The chemotherapy is placed in a large volume of fluid, usually 2 L, and infused into the abdominal cavity where it remains for a specified amount of time; then it is usually drained back out the catheter.
openaire   +2 more sources

Laparoscopical insertion of intraperitoneal catheters for intraperitoneal chemotherapy

Acta Obstetricia et Gynecologica Scandinavica, 2003
Background and methods.  Eight patients (seven clinically negative stage Ill ovarian cancer and one peritoneal mesothelioma) respectively underwent second‐look laparoscopy for staging, adhesiolysis and insertion of an intraperitoneal catheter and fixation of a portal.
Anaf, Vincent, Gangji, Diamon, Simon, Philippe, Saylam, Keziban   +3 more
openaire   +3 more sources

The many faces of intraperitoneal chemotherapy

Surgical Oncology, 2022
Cytoreductive surgery and intraperitoneal chemotherapy may offer chance for cure for patients with peritoneal metastasis. Many variations emerged, causing uncertainty when choosing the most suitable variant. By reviewing variability encountered in the management of peritoneal metastasis, we aim to raise awareness about this issue and hopefully initiate
Hisham Abdel Mageed, Kurt Van Der Speeten, Paul Sugarbaker   +2 more
openaire   +2 more sources

Intraperitoneal Chemotherapy With Cisplatin and Melphalan

JNCI Journal of the National Cancer Institute, 1988
Cisplatin and melphalan given ip exert a synergistic therapeutic effect against ascitic P388 leukemia in mice and have different dose-limiting toxic effects as well as favorable pharmacokinetic characteristics in ip phase I studies. We gave a total of 98 courses of cisplatin (escalated from 40 to 120 mg/m2) and melphalan (escalated from 12 to 30 mg/m2)
M. J. Piccart, J. Abrams, P. F. Dodion, N. Crespeigne, J. P. Sculier, J. C. Pector, C. Finet, C. Nouwijnck, H. Bondue, G. Atassi, Y. Kenis   +10 more
openaire   +3 more sources